-
Mashup Score: 4
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 1
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 5
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 1
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 1
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet
Efficacy and safety of the #SGLT2 inhibitor #empagliflozin vs placebo and the #DPP-4 inhibitor #linagliptin versus placebo in #young #people with type 2 #diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial https://t.co/fdz3fO1cyU #T2D #youth